Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) shares were up 10.6% on Friday after Citigroup raised their price target on the stock from $24.00 to $27.00. Citigroup currently has a hold rating on the stock. Bellicum Pharmaceuticals traded as high as $6.62 and last traded at $6.60. Approximately 1,216,283 shares were traded during trading, an increase of 20% from the average daily volume of 1,012,675 shares. The stock had previously closed at $5.97.
BLCM has been the topic of several other reports. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a report on Friday, January 19th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Raymond James Financial reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price (down from $12.00) on shares of Bellicum Pharmaceuticals in a report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $16.88.
In other news, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $9.33, for a total value of $159,701.61. Following the sale, the chief financial officer now directly owns 31,585 shares in the company, valued at $294,688.05. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total value of $2,248,978.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,165,145 shares of company stock worth $9,696,662. Corporate insiders own 18.77% of the company’s stock.
The stock has a market capitalization of $242.65, a price-to-earnings ratio of -2.21 and a beta of 0.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.chaffeybreeze.com/2018/02/18/bellicum-pharmaceuticals-blcm-trading-up-10-6-on-analyst-upgrade.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.